CIBC Analysts Give kneat.com (TSE:KSI) a C$6.00 Price Target

kneat.com (TSE:KSIGet Free Report) has been given a C$6.00 price objective by investment analysts at CIBC in a research report issued to clients and investors on Tuesday, BayStreet.CA reports. The firm currently has an “outperform” rating on the stock. CIBC’s target price points to a potential upside of 26.85% from the stock’s current price.

Separately, Ventum Cap Mkts upgraded kneat.com to a “strong-buy” rating in a report on Wednesday, August 7th.

Get Our Latest Report on kneat.com

kneat.com Price Performance

Shares of KSI traded down C$0.02 during midday trading on Tuesday, reaching C$4.73. The stock had a trading volume of 59,658 shares, compared to its average volume of 56,090. The company has a debt-to-equity ratio of 95.14, a current ratio of 1.47 and a quick ratio of 1.50. The company has a market capitalization of C$406.78 million, a P/E ratio of -29.56, a P/E/G ratio of 597.67 and a beta of 1.08. The firm’s 50 day moving average price is C$4.76 and its 200-day moving average price is C$4.43. kneat.com has a 52 week low of C$2.68 and a 52 week high of C$5.17.

kneat.com (TSE:KSIGet Free Report) last issued its earnings results on Tuesday, August 6th. The company reported C($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C($0.04). The business had revenue of C$11.68 million for the quarter, compared to analysts’ expectations of C$11.45 million. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. On average, analysts forecast that kneat.com will post -0.12 earnings per share for the current fiscal year.

kneat.com Company Profile

(Get Free Report)

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.

See Also

Receive News & Ratings for kneat.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for kneat.com and related companies with MarketBeat.com's FREE daily email newsletter.